AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7859944
Drug: Insulin concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin concentration increased to 416 +/- 22 pmol/l (step I), 1,170 +/- 79 pmol/l (step II), and 15,936 +/- 1,126 pmol/l (step III) in control subjects; LBF increased from 287 +/- 23 ml.min-1.leg-1 (basal) to 308 +/- 31 ml.min-1.leg-1 (I), 371 +/- 29 ml.min-1.leg-1 (II), and 434 +/- 32 ml.min-1.leg-1 (III).
Trial: 7859944
Drug: Insulin concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin concentration increased to 509 +/- 43 pmol/l (step I), 1,299 +/- 122 pmol/l (step II), and 16,524 +/- 1,916 pmol/l (step III) in NIDDM subjects; LBF increased from 302 +/- 12 ml.min-1.leg-1 (basal) to 362 +/- 9 ml.min-1.leg-1 (I), 409 +/- 17 ml.min-1.leg-1 (II), and 472 +/- 29 ml.min-1.leg-1 (III).
Trial: 21555816
Drug: Nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine (NVP) 200 mg twice daily or 400 mg once daily
Trial: 21555816
Drug: Atazanavir/ritonavir (ATZ/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily
Trial: 12596616
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg (group 1)
Trial: 12596616
Drug: Rocuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.3 mg/kg and Atracurium 0.25 mg/kg (group 2)
Trial: 12596616
Drug: Rocuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.1 mg/kg to prime Atracurium 0.42 mg/kg (priming group)
Trial: 2698570
Drug: Gallopamil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (3 X 60 mg/day)
Trial: 2698570
Drug: Diltiazem (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (3 X 50 mg/day)
Trial: 29103741
Drug: Outpatient physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient physical therapy (OPT)
Trial: 23241739
Drug: Palifermin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palifermin (60 μg/kg/day) i.v. for 3 consecutive days before high-dose Melphalan (HDM)
Trial: 23241739
Drug: Palifermin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palifermin (60 μg/kg/day) i.v. for 3 consecutive days before and after HDM
Trial: 16110353
Drug: Astaxanthin 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin 16 mg/day
Trial: 12520750
Drug: Intraartery chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraartery chemotherapy with Taxol 135 mg/m2 and DDP 80 mg/m2
Trial: 12520750
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy with Taxol 135 mg/m2 and DDP 80 mg/m2
Trial: 2506751
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose intravenous nitroglycerin
Trial: 31833569
Drug: Spironolactone (≤50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (≤50 mg)
Trial: 31833569
Drug: Doxazosin (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (control ≤16 mg)
Trial: 31833569
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (70 mL, ≤11 mmol nitrate)
Trial: 28737971
Drug: Fluticasone Furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone Furoate (FF; 100 μg)
Trial: 28737971
Drug: Vilanterol (VI;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilanterol (VI; 25 μg)
Trial: 18988166
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg intravitreal bevacizumab (IVB group)
Trial: 18988166
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1.25 mg bevacizumab and 2 mg triamcinolone acetonide (IVB+IVT group)
Trial: 10530177
Drug: 0.05% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% NaF solution rinsing (n = 49)
Trial: 10530177
Drug: 1.66 mg
RxNorm normalized name: pyrilamine maleate 1.66 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.66 mg NaF tablet (n = 51)
Trial: 2757958
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) 5 mg/kg per day
Trial: 4817159
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test in the afternoon
Trial: 31479045
Drug: Limited Sampling
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Limited Sampling Strategies (LSS) with sampling at 0, 120, 180, and 240 minutes after the start of the second infusion (LSS15)
Trial: 27780297
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg Nazolam
Trial: 27780297
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg Nazolam
Trial: 27780297
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg intravenous midazolam
Trial: 25855760
Drug: OAC (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (standard triple therapy)
Trial: 25855760
Drug: OA-OACM (hybrid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OA-OACM (hybrid therapy)
Trial: 24144653
Drug: Naltrexone sustained-release/bupropion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone sustained-release/bupropion sustained-release (NB)
Trial: 11547370
Drug: 5-step lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-step lateral release sequence (PCL, posterolateral capsule, IT band, PT, LCL)
Trial: 7800954
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily oral theophylline (800 mg/day)
Trial: 7800954
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily inhaled budesonide (0.8 mg/day)
Trial: 29546857
Drug: H1-coil rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1-coil rTMS as an add-on to stable pharmacotherapy
Trial: 29546857
Drug: Figure-8-coil rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Figure-8-coil rTMS as an add-on to stable pharmacotherapy
Trial: 29546857
Drug: Stable pharmacotherapy
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable pharmacotherapy alone
Trial: 22913800
Drug: Perampanel (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (titrated to a maximum of 12 mg/day over 12 weeks, maintained for up to 424 weeks)
Trial: 18435373
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L-Pop (LP)
Trial: 14655913
Drug: Cabergoline (upward
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (upward titration from 0.5 mg to 2 mg in a single evening dose)
Trial: 3888102
Drug: Ribavirin small-particle
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin small-particle aerosol treatment (2.4 g over 42 h during 68 h of hospitalization)
Trial: 31574097
Drug: Football group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Football group (FG) - 6 months of free-of-charge football training twice weekly
Trial: 26204844
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate (SrR) 2 g daily
Trial: 22930293
Drug: Clindamycin vaginal
RxNorm normalized name: clindamycin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin vaginal cream (CVC) for three days
Trial: 22930293
Drug: Clindamycin vaginal
RxNorm normalized name: clindamycin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin vaginal cream (CVC) additional seven-day course
Trial: 22930293
Drug: Clindamycin vaginal
RxNorm normalized name: clindamycin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin vaginal cream (CVC) additional treatment
Trial: 22930293
Drug: Placebo additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo additional treatment
Trial: 22930293
Drug: Clindamycin vaginal
RxNorm normalized name: clindamycin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin vaginal cream (CVC)
Trial: 20613550
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg 12 hours before PCI, with a further 40 mg preprocedure dose)
Trial: 2350209
Drug: Cocaine hydrochloride
RxNorm normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine hydrochloride (40 mg intravenously)
Trial: 111274
Drug: Clorgyline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorgyline treatment for 4 weeks
Trial: 111274
Drug: Pargyline treatment
RxNorm normalized name: pargyline
DrugBank: Pargyline (DB01626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pargyline treatment
Trial: 31863189
Drug: Diphenhydramine 30
RxNorm normalized name: pseudoephed/diphenhydramine 30 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 30 mg intravenously after induction of general anesthesia
Trial: 30504445
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg single infusion)
Trial: 25533540
Drug: Pramipexole (PPX)
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pramipexole (PPX) 0.25 mg to 0.75 mg, taken 2-3 hours before bedtime for 12 weeks
Trial: 11146393
Drug: bivalent HAV/HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent HAV/HBV vaccine
Trial: 9557092
Drug: Antibiotics and
RxNorm normalized name: Antibiotics and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics and Gamma‐Venin P
Trial: 8354633
Drug: AZT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT treatment
Trial: 3524509
Drug: D-phenylalanine (DPA)
RxNorm normalized name: Phenylalanine
DrugBank: D-Phenylalanine (DB02556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-phenylalanine (DPA) 250 mg orally four times a day for four weeks
Trial: 29128692
Drug: Aspirin 975
RxNorm normalized name: aspirin 975 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 975 mg tid and omeprazole 20 mg od
Trial: 26155004
Drug: 2% papain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% papain gel
Trial: 26155004
Drug: 2% carboxymethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% carboxymethyl cellulose gel
Trial: 21814138
Drug: recombinant GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant GH (rGH) administration, 6 IU daily
Trial: 19487903
Drug: Nonnucleoside reverse
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonnucleoside reverse transcriptase inhibitor (NNRTI) + protease inhibitor
Trial: 19487903
Drug: Classical nucleoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical nucleoside reverse transcriptase inhibitor (NRTI) based regimen
Trial: 15488341
Drug: Oral methylphenidate
RxNorm normalized name: methylphenidate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylphenidate (MPH) 0.5 mg/kg
Trial: 9475306
Drug: Rice oral
RxNorm normalized name: Licorice Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice oral rehydration solution (ORS)
Trial: 7524313
Drug: Fresh frozen
RxNorm normalized name: Fresh frozen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh frozen plasma (FFP) 20 ml/kg
Trial: 2856598
Drug: Pirprofen administered
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pirprofen administered by iontophoresis
Trial: 2856598
Drug: Lysine soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine soluble aspirin administered by iontophoresis
Trial: 25672646
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation (n = 60)
Trial: 23534020
Drug: MDPB-containing self-etching
RxNorm normalized name: fish oil (containing omega-3 acids)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDPB-containing self-etching primer with fluoride-free bonding agent
Trial: 23534020
Drug: MDPB-free self-etching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDPB-free self-etching primer with fluoride-containing bonding agent
Trial: 19762153
Drug: Ibuprofen 600mg
RxNorm normalized name: IBUPROFEN 600MG TAB
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600mg
Trial: 11768323
Drug: Ibuprofen 1200mg
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 1200mg
Trial: 27025240
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor letrozole (Lz; 2.5 mg/day; n = 16)
Trial: 21136235
Drug: Self-management program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management program FIBS (six modules including information about fatigue and behavioral therapy strategies)
Trial: 7485885
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac 100 mg
Trial: 22980293
Drug: Intramyocardial injections
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injections of autologous bone-marrow derived mesenchymal stromal cells (MSCs)
Trial: 16444382
Drug: Trimethoprim‐sulfamethoxazole (800/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim‐sulfamethoxazole (800/160 mg/day, 5 days a week)
Trial: 12445024
Drug: Single 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1 h infusion of E7070
Trial: 12445024
Drug: Daily 1
RxNorm normalized name: Beauty 360 Daily 1.2% Moisturizing Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 1 h infusion of E7070 for 5 days
Trial: 15934131
Drug: Monthly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly telephone contact
Trial: 12364304
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy plus telephone contact
Trial: 30932787
Drug: Crude palm
RxNorm normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crude palm oil fortified cookies (providing 2152 μg of β-carotene)
Trial: 30342554
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) therapy - 16 mg per day (8 mg twice daily, days 1 to 4), halved every 3 days until 0.5 mg a day on day 19, stopped on day 20.
Trial: 26407272
Drug: bivalent rLP2086
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent rLP2086 (3 doses)
Trial: 26407272
Drug: bivalent rLP2086
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent rLP2086 (2 doses)
Trial: 26407272
Drug: bivalent rLP2086
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent rLP2086 (2 or 3 doses)
Trial: 20465648
Drug: 20mg isotretinoin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg isotretinoin, 3 times per week, nightly moisturizer, and daily sunscreen for three months
Trial: 18022044
Drug: Stepped-care intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care intervention group (12 weeks of optimized antidepressant management followed by six sessions of a pain self-management program)
Trial: 12551867
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion (0.125 g/min) for 120 minutes
Trial: 12551867
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion for 120 minutes
Trial: 10778516
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (2 vials over 1 hour, followed by 2 vials over 4 hours, repeated 4 hourly until clotting parameters normalized and then 2 vials as infusion over 24 hours)
Trial: 10778516
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (2 vials over 1 hour, followed by 1 vial over four hours, repeated 4 hourly until clotting parameters normalized and then 1 vial as infusion over 24 hours)
Trial: 8657463
Drug: Scanning started
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Scanning started at 80% of the contrast injection time
Trial: 8657463
Drug: Scanning started
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Scanning started at 100% of the contrast injection time
Trial: 8657463
Drug: Scanning started
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Scanning started at 150% of the contrast injection time
Trial: 2050170
Drug: Clomipramine (25‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (25‐50 mg t.i.d.)
Trial: 2050170
Drug: Alprazolam (0.25‐0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.25‐0.75 mg t.i.d.)
Trial: 6353430
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg feprazone 3-times a day
Trial: 6353430
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg feprazone twice a day
Trial: 31486072
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual or wait-list control (n = 221)
Trial: 29786898
Drug: Modified Prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Prolonged Exposure (mPE) therapy for PTSD
Trial: 29786898
Drug: Non-trauma-focused comparison
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-trauma-focused comparison treatment
Trial: 27273910
Drug: Free lutein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free lutein (10 mg daily for 3 months)
Trial: 27273910
Drug: Lutein esters
RxNorm normalized name: lutein esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein esters (20 mg daily for 3 months, equivalent to 10 mg of free lutein)
Trial: 24287601
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of siltuximab
Trial: 24287601
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of siltuximab (predicted)
Trial: 19874316
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects of active treatment
Trial: 9499103
Drug: Combination antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antiretroviral therapy
Trial: 18086590
Drug: PUVA monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA monotherapy
Trial: 30267277
Drug: CO2 laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 laser irradiation (L)
Trial: 30267277
Drug: Fluoride treatment
RxNorm normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoride treatment (F)
Trial: 30267277
Drug: Combined fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined fluoride and laser treatment (FL)
Trial: 30267277
Drug: No treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment, control (C)
Trial: 22474057
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins (2 mg folic acid, 25 mg vitamin B(6), 500 μg vitamin B(12))
Trial: 14991555
Drug: Lactulose syrup
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose syrup (routine administration twice daily)
Trial: 14991555
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (laxative on indication)
Trial: 9920062
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement therapy (3 or 6 microg/kg x day, s.c.) for 3 months
Trial: 2123791
Drug: Pravastatin 5
RxNorm normalized name: pravastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 5 mg b.d. for 8 weeks followed by 10 mg b.d. for 8 weeks (Group I)
Trial: 2123791
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg b.d. for 8 weeks followed by 20 mg b.d. for 8 weeks (Group II)